In the realm of drug treatments, especially those involving high-dose protein-based therapeutics, the limitation of being available solely as intravenous (IV) infusions poses significant challenges. These protein therapeutics necessitate delivery as dilute solutions to prevent protein aggregation and maintain stability, often requiring high doses for efficacy. Consequently, patients undergo time-consuming treatments, and healthcare infrastructure must support trained personnel for IV administration.
A groundbreaking advancement has emerged in the form of a novel delivery platform that enables these drugs to be stored and dispensed at significantly higher concentrations. Through this innovative formulation technique, numerous protein therapeutics can potentially be administered through standard syringes or autoinjector devices, revolutionizing the treatment landscape.
Recently published inScience Translational Medicine, the research introduces a paper titled “Ultra-high concentration biologic therapeutics enabled by spray drying with a glassy surfactant excipient,” shedding light on this transformative drug delivery approach. Dr. Eric Appel, an associate professor at Stanford University, emphasizes the versatility of this platform, highlighting its potential to simplify the injection process for a wide range of biologic drugs, consequently shifting from lengthy clinic-based IV infusions to swift autoinjector applications at the patient’s convenience.
Traditionally, high concentrations of protein therapeutics are predisposed to aggregation, leading to increased viscosity that impedes injectability or triggers immune responses. To address this challenge, Appel and his team engineered a polyacrylamide copolymer named MoNi, characterized by a notably high glass transition temperature. Unlike conventional drug additives that soften at elevated temperatures, MoNi retains a solid, glass-like state. By incorporating MoNi into a water-protein drug mixture, aerosolizing it into minute droplets, and subsequently evaporating the water through spray drying, the researchers successfully generated a fine powder comprising protein particles enveloped in MoNi coatings.
The resulting powder, when blended into a liquid suspension, maintains the individuality of drug particles without dissolving them. The MoNi coating acts as a barrier against particle agglomeration, preserving the proteins in a desiccated, stable state until the liquid suspension is introduced into the body. This innovative approach ensures that the spherical microparticles, equipped with smooth surfaces, can flow through fine needles for injection, enabling the achievement of remarkably high drug concentrations.
Experimental validation of this methodology encompassed three distinct proteins—albumin, human immunoglobulin, and a monoclonal antibody for COVID-19 treatment. Impressively, concentrations exceeding 500 mg/mL were attained, surpassing typical liquid injection concentrations twofold. Furthermore, these formulations exhibited enhanced stability across a broader temperature range compared to conventional liquid forms.
The utilization of spray drying in pharmaceutical processes is a well-established practice, and the safety evaluation of MoNi in various preclinical models has reported no adverse effects, instilling optimism in the researchers regarding its clinical approval. A local startup has already secured licensing for this technology, focusing on refining the process for developing innovative drug products that were once deemed unattainable due to stability concerns with existing technologies.
In conclusion, this pioneering drug delivery platform represents a significant leap in stabilizing proteins and facilitating the development of novel drug products that were previously unfeasible. The enhanced convenience and efficacy offered by this approach not only alleviate the burdens associated with traditional IV treatments but also unlock a realm of possibilities for administering diverse biologic drugs.
- The novel spray drying platform offers a transformative solution for enhancing drug delivery efficiency and stability.
- MoNi’s high glass transition temperature plays a pivotal role in safeguarding protein therapeutics during the formulation process.
- The innovative approach enables achieving unprecedented drug concentrations and improved stability profiles.
- Collaborative efforts between academia and industry are crucial for translating cutting-edge research into tangible healthcare solutions.
Tags: formulation, protein aggregation, biotech
Read more on genengnews.com